Loss of prolyl carboxypeptidase in two-kidney, one-clip goldblatt hypertensive mice

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Grobe, Nadja ^a   Leiva, Orly ^a   Morris, Mariana ^b   Elased, Khalid M ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b affiliation with Nova Southeastern College of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; PROLINE CARBOXYPEPTIDASE; PROLYL ENDOPEPTIDASE; PROTEASE PROLYL CARBOXYPEPTIDASE; RENIN; UNCLASSIFIED DRUG; CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; DISEASE EXACERBATION; DOWN REGULATION; ENZYME ACTIVITY; GLOMERULUS; HORMONE METABOLISM; IMMUNOFLUORESCENCE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY TUBULE; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; RENAL ARTERY; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; TELEMETRY; URINARY ALBUMIN EXCRETION; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; KIDNEY ARTERY; METABOLISM; PHYSIOLOGY;

ANIMALIA; MUS;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARBOXYPEPTIDASES; HYPERTENSION, RENOVASCULAR; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; RENAL ARTERY; RENIN;

EID: 84923359254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117899     Document Type: Article

References (83)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047. 298/17/2038 [pii]; doi: 10.1001/jama.298.17.2038 PMID: 17986697
2. Marut W, Kavian N, Servettaz A, Hua-Huy T, Nicco C et al. (2013) Angiotensin II receptor blockade ameliorates systemic fibrosis in the mouse. Arthritis Rheum. doi: 10.1002/art.38169 PMID: 24285000
3. Bernstein KE, Sayeski PP, Doan T, Farmer PK, Ali MS (2001) Signal transduction pathways of angiotensin II in the kidney. Contrib Nephrol 16-33. PMID: 11705281
4. Lavoz C, Rodrigues-Diez R, Benito-Martin A, Rayego-Mateos S, Rodrigues-Diez RR et al. (2012) Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. PLoS One 7: e40490. PONE-D-12-05960 [pii]. doi: 10.1371/journal.pone.0040490 PMID: 22792351
5. Giani JF, Mayer MA, Munoz MC, Silberman EA, Hocht C et al. (2009) Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol Endocrinol Metab 296: E262-E271. doi: 10.1152/ajpendo.90678.2008 PMID: 19001546
6. Ren Y, Garvin JL, Carretero OA (2002) Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799-802. PMID: 11897767
7. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas 1. Proc Natl Acad Sci U S A 100: 8258-8263. PMID: 12829792
8. Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC et al. (2010) Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 55: 889-896. HYPERTENSIONAHA.110.149815 [pii]; doi: 10.1161/HYPERTENSIONAHA.110.149815 PMID: 20212262
9. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO et al. (2008) Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 51: 574-580. HYPERTENSIONAHA. 107.102764 [pii]; doi: 10.1161/HYPERTENSIONAHA.107.102764 PMID: 18180400
10. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S et al. (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363. 00317.2005 [pii]; doi: 10.1152/ajpheart.00317.2005 PMID: 16024575
11. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M et al. (2008) Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326. CIRCRESAHA. 108.184911 [pii]; doi: 10.1161/CIRCRESAHA.108.184911 PMID: 18845809
12. Shah A, Oh YB, Lee SH, Lim JM, Kim SH (2012) Angiotensin-(1-7) attenuates hypertension in exercise-trained renal hypertensive rats. Am J Physiol Heart Circ Physiol 302: H2372-H2380. ajpheart.00846.2011 [pii]; doi: 10.1152/ajpheart.00846.2011 PMID: 22467306
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9. PMID: 10969042
14. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS et al. (2004) Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43: 1120-1125. PMID: 15078862
15. Ye M, Wysocki J, William J, Soler MJ, Cokic I et al. (2006) Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075. PMID: 17021266
16. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD et al. (2006) ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139. PMID: 16804085
17. Giani JF, Munoz MC, Pons RA, Cao G, Toblli JE et al. (2011) Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 300: F272-F282. doi: 10.1152/ajprenal.00278.2010 PMID: 20962118
18. Alghamri MS, Weir NM, Anstadt MP, Elased KM, Gurley SB et al. (2013) Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. J Cardiovasc Pharmacol Ther 18: 138-151. 1074248412460124 [pii]; doi: 10.1177/1074248412460124 PMID: 23043153
19. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J et al. (2009) Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54: 365-371. HYPERTENSIONAHA. 108.125468 [pii]; doi: 10.1161/HYPERTENSIONAHA.108.125468 PMID: 19564552
20. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C et al. (2010) Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55: 90-98. doi: 10.1161/HYPERTENSIONAHA.109.138420 PMID: 19948988
21. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK et al. (2010) Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 106: 373-382. CIRCRESAHA. 109.208645 [pii]; doi: 10.1161/CIRCRESAHA.109.208645 PMID: 19926873
22. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP et al. (2005) Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90: 783-790. expphysiol.2005.031096 [pii]; doi: 10.1113/expphysiol.2005.031096 PMID: 16049057
23. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540-2548. doi: 10.2337/db09-0782 PMID: 20660625
24. Verma A, Shan ZY, Lei B, Yuan LH, Liu X et al. (2012) ACE2 and Ang-(1-7) Confer Protection Against Development of Diabetic Retinopathy. Molecular Therapy 20: 28-36. doi: 10.1038/mt.2011.155 PMID: 21792177
25. Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY et al. (2010) Angiotensin-Converting Enzyme 2 Overexpression Remarkably Ameliorated Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition. Mol Med. doi: 10.2119/molmed.2010.00204 PMID: 21203694
26. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F et al. (2012) Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82: 292-303. ki201283 [pii]; doi: 10.1038/ki.2012.83 PMID: 22475818
27. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI et al. (2010) Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 55: 166-171. HYPERTENSIONAHA.109.141622 [pii]; doi: 10.1161/HYPERTENSIONAHA.109.141622 PMID: 19948986
28. Monteiro MB, Senador D, Zhang WF, Morris M, Elased KM (2008) Balance of ACE and ACE2 in diabetes: Decreased renal ACE2 activity in hypertensive db/db diabetic mice. Hypertension 52: E91.
29. Gurley SB, Allred A, Le TH, Griffiths R, Mao L et al. (2006) Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218-2225. 05960 [pii]. doi: 10.1172/JCI16980 PMID: 16878172
30. Gurley SB, Coffman TM (2008) Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp Physiol 93: 538-542. doi: 10.1113/expphysiol.2007.040014 PMID: 18376006
31. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M et al. (2006) Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47: 718-726. PMID: 16505206
32. Zhong J, Guo D, Chen CB, Wang W, Schuster M et al. (2011) Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57: 314-322. HYPERTENSIONAHA.110.164244 [pii]; doi: 10.1161/HYPERTENSIONAHA.110.164244 PMID: 21189404
33. Welches WR, Brosnihan KB, Ferrario CM (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neprilysin. Life Science 52: 1461-1480. PMID: 8387132
34. Tan F, Morris PW, Skidgel RA, Erdös EG (1993) Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem 268: 16631-16638. PMID: 8344943
35. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM (1992) In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19: 692-696. PMID: 1317352
36. Rioli V, Kato A, Portaro FC, Cury GK, te KK et al. (1998) Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant endopeptidase 3.4.24.15. Biochem Biophys Res Commun 250: 5-11. PMID: 9735321
37. Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE et al. (2013) Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol 304: C945-C953. ajpcell.00346.2012 [pii]; doi: 10.1152/ajpcell.00346.2012 PMID: 23392115
38. Grobe N, Elased KM, Cool DR, Morris M (2012) Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302: E1016-E1024. ajpendo.00515.2011 [pii]; doi: 10.1152/ajpendo.00515.2011 PMID: 22318946
39. Yang HYT, Erdos EG, Chiang TS, Jenssen TA, Rodgers JG (1970) Characteristics of An Enzyme That Inactivates Angiotensin Ii (Angiotensinase C). Biochemical Pharmacology 19: 1201-1211.
40. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG (1978) Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927-5931. PMID: 28321
41. Nomura M, Nomura S, Mitsui T, Suzuki M, Kobayashi H et al. (2005) Possible involvement of amino-peptidase A in hypertension and renal damage in Dahl salt-sensitive rats. Am J Hypertens 18: 538-543. S0895-7061(04)01149-5 [pii]; PMID: 15831365
42. Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA et al. (2011) Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology 152: 1582-1588. en.2010-1070 [pii]; doi: 10.1210/en.2010-1070 PMID: 21303953
43. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P et al. (1996) Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A 93: 11968-11973. PMID: 8876246
44. Fyhrquist F, Saijonmaa O (2008) Renin-angiotensin system revisited. J Intern Med 264: 224-236. doi: 10.1111/j.1365-2796.2008.01981.x PMID: 18793332
45. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y et al. (2001) Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38: 1382-1387. PMID: 11751722
46. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG (1978) Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927-5931. PMID: 28321
47. Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT et al. (2011) Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117: 3929-3937. blood-2010-11-318527 [pii]; doi: 10.1182/blood-2010-11-318527 PMID: 21297000
48. Jeong JK, Diano S (2013) Prolyl carboxypeptidase and its inhibitors in metabolism. Trends Endocrinol Metab 24: 61-67. S1043-2760(12)00201-9 [pii]; doi: 10.1016/j.tem.2012.11.001 PMID: 23245768
49. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E et al. (2009) Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest 119: 2291-2303. doi: 10.1172/JCI37209 PMID: 19620781
50. Shariat-Madar Z, Mahdi F, Schmaier AH (2002) Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277: 17962-17969. doi: 10.1074/jbc.M106101200 M106101200 [pii]. PMID: 11830581
51. Moreira CR, Schmaier AH, Mahdi F, da MG, Nader HB et al. (2002) Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 523: 167-170. S0014579302029800 [pii]. PMID: 12123826
52. Odya CE, Erdos EG (1981) Human prolylcarboxypeptidase. Methods Enzymol 80 Pt C: 460-466.
53. Adams GN, Stavrou EX, Fang C, Merkulova A, Alaiti MA et al. (2013) Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood. blood-2012-10-460360 [pii]; doi: 10.1182/blood-2012-12-473777 PMID: 24501760
54. Xu S, Lind L, Zhao L, Lindahl B, Venge P (2012) Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin Chem 58: 1110-1115. clinchem.2011.179291 [pii]; doi: 10.1373/clinchem.2011.179291 PMID: 22539806
55. Wang L, Feng Y, Zhang Y, Zhou H, Jiang S et al. (2006) Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol 195: 162-171. S0002-9378(06)00151-7 [pii]; doi: 10.1016/j.ajog.2006.01.079 PMID: 16681991
56. Zhang Y, Hong XM, Xing HX, Li JP, Huo Y et al. (2009) E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl) 122: 2461-2465. PMID: 20079160
57. Goldblatt H, Lynch J, Hanzal RF, Summerville WW (1934) STUDIES ON EXPERIMENTAL HYPERTENSION: I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA. J Exp Med 59: 347-379. PMID: 19870251
58. Cote I, Boucher D, Lebel M (2001) Renovascular hypertension and focal segmental glomerulosclerosis in the contralateral kidney. J Hum Hypertens 15: 143-144. doi: 10.1038/sj.jhh.1001145 PMID: 11317195
59. Elased KM, Cool DR, Morris M (2005) Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 46: 953-959. PMID: 16103259
60. Cervenka L, Horacek V, Vaneckova I, Hubacek JA, Oliverio MI et al. (2002) Essential role of AT1A receptor in the development of 2K1C hypertension. Hypertension 40: 735-741. PMID: 12411470
61. Cervenka L, Vaneckova I, Huskova Z, Vanourkova Z, Erbanova M et al. (2008) Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice. Journal of Hypertension 26: 1379-1389. doi: 10.1097/HJH.0b013e3282fe6eaa PMID: 18551014
62. Lazartigues E, Lawrence AJ, Lamb FS, Davisson RL (2004) Renovascular hypertension in mice with brain-selective overexpression of AT1a receptors is buffered by increased nitric oxide production in the periphery. Circ Res 95: 523-531. doi: 10.1161/01.RES.0000140892.86313.c2 01. RES.0000140892.86313.c2 [pii]. PMID: 15284190
63. Pliquett RU, Benkhoff S, Jung O, Brandes RP (2014) Sympathoactivation and rho-kinase-dependent baroreflex function in experimental renovascular hypertension with reduced kidney mass. BMC Physiol 14: 4. 1472-6793-14-4 [pii]; doi: 10.1186/1472-6793-14-4 PMID: 24946879
64. Prieto MC, Gonzalez-Villalobos RA, Botros FT, Martin VL, Pagan J et al. (2011) Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 300: F749-F755. ajprenal.00383.2009 [pii]; doi: 10.1152/ajprenal.00383.2009 PMID: 21209009
65. Qin XP, Zeng SY, Tian HH, Deng SX, Ren JF et al. (2009) Involvement of prolylcarboxypeptidase in the effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive rats. Clin Exp Pharmacol Physiol 36: 319-324. CEP5079 [pii]; doi: 10.1111/j.1440-1681.2008.05079.x PMID: 19018804
66. Lorenz JN, Lasko VM, Nieman ML, Damhoff T, Prasad V et al. (2011) Renovascular hypertension using a modified two-kidney, one-clip approach in mice is not dependent on the alpha1 or alpha2 Na-K-ATPase ouabain-binding site. Am J Physiol Renal Physiol 301: F615-F621. ajprenal.00158.2011 [pii]; doi: 10.1152/ajprenal.00158.2011 PMID: 21632957
67. Fujino T, Nakagawa N, Yuhki K, Hara A, Yamada T et al. (2004) Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 114: 805-812. doi: 10.1172/JCI21382 PMID: 15372104
68. Kost CK Jr., Li P, Pfeifer CA, Jackson EK (1994) Telemetric blood pressure monitoring in benign 2-kidney, 1-clip renovascular hypertension: effect of chronic caffeine ingestion. J Pharmacol Exp Ther 270: 1063-1070. PMID: 7932154
69. Brosius FC, Pennathur S (2013) How to find a prognostic biomarker for progressive diabetic nephropathy. Kidney Int 83: 996-998. ki201358 [pii]; doi: 10.1038/ki.2013.58 PMID: 23728003
70. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 5: 397-406. nrneph.2009.91 [pii]; doi: 10.1038/nrneph.2009.91 PMID: 19556994
71. Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL et al. (2013) Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 27: 123-127. S1056-8727(12)00278-4 [pii]; doi: 10.1016/j.jdiacomp.2012.09.010 PMID: 23182925
72. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI et al. (2010) The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 10: 37-42. doi: 10.1007/s11892-009-0080-z PMID: 20425065
73. Brown JJ, Davies DL, Morton JJ, Robertson JI, Cuesta V et al. (1976) Mechanism of renal hypertension. Lancet 1: 1219-1221. PMID: 58263
74. Keddis MT, Garovic VD, Bailey KR, Wood CM, Raissian Y et al. (2010) Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 25: 3615-3622. gfq269 [pii]; doi: 10.1093/ndt/gfq269 PMID: 20501460
75. Navar LG, Zou L, Von TA, Tarng WC, Imig JD et al. (1998) Unraveling the Mystery of Goldblatt Hypertension. News Physiol Sci 13: 170-176. PMID: 11390784
76. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA et al. (2009) Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 20: 363-379. ASN.2008040406 [pii]; doi: 10.1681/ASN.2008040406 PMID: 19056867
77. Shariat-Madar Z, Mahdi F, Schmaier AH (2004) Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 103: 4554-4561. doi: 10.1182/blood-2003-07-2510 2003-07-2510 [pii]. PMID: 14996700
78. da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD et al. (2010) ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119: 385-394. CS20090554 [pii]; doi: 10.1042/CS20090554 PMID: 20528771
79. Zhu L, Carretero OA, Liao TD, Harding P, Li H et al. (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56: 384-390. HYPERTENSIONAHA.110.155051 [pii]; doi: 10.1161/HYPERTENSIONAHA.110.155051 PMID: 20606103
80. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R et al. (2001) Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 280: H1821-H1829. PMID: 11247797
81. Girolami JP, Praddaude F, Ader JL, Tran VT, Eche JP et al. (1983) Bilateral urinary kallikrein excretion in the Goldblatt hypertensive rat. Eur Heart J 4 Suppl G: 67-72. PMID: 6363081
82. Carretero OA, Scicli AG (1978) The renal kallikrein-kinin system in human and in experimental hypertension. Klin Wochenschr 56 Suppl 1: 113-125. PMID: 366276
83. Hulthen UL, Lecerof H, Hokfelt B (1977) Renal venous output of kinins in patients with hypertension and unilateral renal artery stenosis. Acta Med Scand 202: 189-191. PMID: 910636